Bionyra Pharma
Bionyra Pharma launches with an oversubscribed €143M Series A to develop mono and multispecific antibodies for inflammatory and immunological diseases.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Nearfield Instruments, Bionyra Pharma, Isometric — chip metrology, biopharma and AI certification become infrastructure — Daily News June 22, 2026
Listen to the episodeAbout Bionyra Pharma
Bionyra Pharma is a clinical-stage biopharma company based between Paris and Boston. It launched with a $165 million, approximately €143 million, Series A co-led by Jeito Capital and Sofinnova Partners. The company is developing next-generation biologics for immune-mediated diseases such as atopic dermatitis and inflammatory bowel disease, starting from a pipeline that includes clinical and IND-stage assets.
The Story
Bionyra was seed financed and co-founded by Sofinnova Partners alongside Frédéric Marrache, a former Sanofi R&D executive and now CEO, in 2025.
How Bionyra Pharma works
Business Model
Clinical-stage biotech development with potential monetisation through licensing, pharma partnerships, milestones and future commercialisation.
Revenue Model
No disclosed commercial revenue; expected model based on licensing, partnerships, milestones and potential commercialisation of approved therapies.
Products & Services
Key Products
- BYN-001
- BYN-002
- BYN-003
Core Use Cases
- Atopic dermatitis
- Inflammatory bowel disease
- Immune-mediated inflammatory diseases
Market & Clients
Key Customers
Patients with severe immunological and inflammatory diseases; at clinical stage, no approved commercial products are indicated by the sources.
Geographic Presence
How Bionyra Pharma competes
Competitive Advantages
- Pipeline with clinical and IND-stage assets
- Mono and multispecific antibodies
- Half-life extension engineering
- Sanofi-experienced team and specialist investors
How Bionyra Pharma grows
Growth Strategy
Advance clinical studies and generate patient validation in dermatology and IBD.
Distribution Model
Clinical-stage drug development; potential pharma partnerships, licensing or future commercialisation.
Moat (Defensibility)
Combination of licensed therapeutic assets, immunology clinical know-how and specialist capital to move quickly toward clinical validation.
Regulatory Context
Drug development subject to clinical and regulatory approvals, including authorities such as EMA and FDA.
Key Risks
- Clinical risk
- Regulatory risk
- Intense competition in immunology
- High cost and long timelines of drug development
Strategic Insights
- Biotech capital rewards pipelines with clear clinical rationale and assets close to human validation.
- The Paris-Boston bridge remains important for scaling European life-sciences companies.
- Sanofi Ventures' participation strengthens the industrial relevance of the case.
Funding & Investors
Funding Rounds
- 2026 - Series A: €143M / $165M
Lead: Jeito Capital, Sofinnova Partners
Key Investors
Founding Team
Founders
Key Executives
- Frédéric Marrache - CEO
Key Metrics
Lessons from Bionyra Pharma
- In biotech, scientific leadership and asset quality matter more than market storytelling.
- A large early round makes sense when it funds costly clinical development and regulatory milestones.
- Specialist investors can operate as company builders, not only capital providers.
Similar Startups
Signacor Therapeutics
Paris-based biotech specializing in next-generation therapies for rare cardiovascular diseases using gene editing and oligonucleotide platforms.
Read AnalysisTREEFROG THERAPEUTICS
Cell therapy company making iPS-derived treatments safer, more efficient, and more affordable for patients with serious diseases.
Read AnalysisCare Forward
Digital health platform connecting patients with personalized care coordination.
Read Analysis